Seattle Genetics Presents Preclinical Data On Its Antibody-Drug Conjugate Technology And SGN-33 Program At AACR
Apr 18th 2008Drug InformationCancer
Seattle Genetics, Inc. (NASDAQ:SGEN) announced data from multiple poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) highlighting preclinical findings with its proprietary antibody-drug conjugate (ADC) technology. Preclinical data were also presented on SGN-33, a humanized antibody that is in clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
